Chloroquine and Amodiaquine
Chloroquine
and amodiaquine are 4-aminoquinolines which were products of American research
during World War II, though there are reliable indications that chloroquine had
been synthesised by the Germans several years earlier as Resochin, which is incidentally a very popular brand name for
chloroquine even today. Other members of the group of 4-aminoquinolones include
broxyquinoline, cycloquine, di-iodohydroxyquine, hydroxychloroquine, mepacrine,
pamaquine, pentaquine, and plasmocid.
Amodiaquine
is actually a congener of chloroquine and is no longer used abroad owing to its
propensity for causing hepatic damage and agranulocytosis. Another related
compound, hydroxychloroquine is preferred in the treatment of rheumatoid arthritis
and SLE in place of chloroquine since it is less oculotoxic in the long run.
Chloroquine is well absorbed orally
and parenterally (intra-muscular and subcutaneous injection). It has a large
volume of distribution, and is moderately protein-bound (50%). Peak plasma
levels are achieved in 2 to 3 hours. There is a large amount of tissue storage
with chloroquine. Chloroquine accu-mulates especially in heart, kidney, liver,
pancreas, lung and spleen, and is strongly bound in melanin-containing cells
(eye and skin). Excretion occurs in the urine, upto 20% of the drug being
unchanged. The main metabolite is monodesethyl chloro-quine. Renal excretion of
chloroquine and its major metabolite is enhanced by acidification of the urine.
·
Long-term effects of prolonged chloroquine therapy include
malaise, anorexia, pruritus, urticaria, haemolytic anaemia,
methaemoglobinaemia, retinopathy, psychosis, seizures, convulsions, vertigo,
headache, and convulsions. Sudden respiratory apnoea can occur. CVS
manifesta-tions comprise hypotension, atrioventricular conduction defects, and
cardiac arrhythmias. Hypokalaemia is often present. Cardiomyopathy has also
been reported in several cases.
·
In a retrospective chart review, chronic therapy with
hydroxychloroquine was found to be less toxic to the retina than chloroquine
therapy. Effects of chloroquine retinopathy include pigmentary stippling,
mottling, a “bull’s eye” pattern of macular hyperpigmentation, attenuation of
the retinal arteries, pale optic discs, disturbance of colour vision, loss of
central vision scotoma and visual field defects.
·
Psychosis as the sole adverse effect has been reported often
with therapeutic use of chloroquine, especially in children. Capgras’ syndrome
(the misguided belief that a familiar person has been replaced by an imposter),
was reported in the case of an 8-year-old girl who was treated with therapeutic
chloroquine for three days. Psychiatric disturbances may appear as early as
within 24 hours of the first dose, or as late as several days after the final
dose. A retrospective review of chloroquine-induced psychiatric complications
(organic psychoses, schizophrenia, depres-sion, and anxiety) found that
symptoms appeared after intake of 2.4 to 6 grams of chloroquine between 4 and
40 days after onset of therapy. The exact mechanism remains unknown.
·
Acute overdose with chloroquine can cause nausea, vomiting,
diarrhoea, haemorrhagic gastritis, hyperexcit-ability, agitation, convulsions,
coma, QRS widening, ventricular arrhythmias, hypotension, shock, cardiac
arrest, respiratory arrest and death.
o The following are indications of
severe toxicity: systolic BP < 90 mmHg, QRS duration >110 milliseconds,
and hypokalaemia (K+< 3.0 mEq).
o Chloroquine overdose has resulted in
life-threatening cardiotoxic effects. The primary effects include hypo-tension,
vasodilation, ECG abnormalities (prolonged PR, QRS, and QT interval),
ventricular arrhythmias and cardiovascular collapse. Cardiac arrest may occur rapidly,
within 1 to 2 hours following ingestion. Hypotension is frequent and may
progress rapidly to cardiogenic shock with increased central venous pres-sure
following chloroquine or hydroxychloroquine overdose. Severe hypokalaemia (1 to
2 mmol/L) is frequent in severe intoxication.
·
Amodiaquine toxicity results in spasticity, seizures,
convul-sions, dysarthria, syncope, hepatitis and agranulocytosis.
·
Hydroxychloroquine poisoning produces vomiting, seizures,
arrhythmias (less common), myocarditis and myopathy and hepatic failure.
·
Chloroquine is wrongly believed to be an effective
aborti-facient by the lay public. It is true that stillbirths and spon-taneous
abortions have occurred after taking chloroquine or hydroxychloroquine, but
these drugs are by no means reliable abortifacients.
■■ Chloroquine: 3 to 6
grams. As little as 2.25 to 3 grams of chloroquine may be fatal in an adult. About 2 to 3
times the therapeutic dose may be fatal in children. Estimated fatal dose is 30
to 50 mg chloroquine base/kg.
■■Hydroxychloroquine: 10 to 20 grams.
Adults have developed hypotension and ventricular arrhythmias after ingesting
12 to 22 grams.
■■ Chloroquine
toxicity is dose dependant. The following has been observed in adults:
o Dose
ingested greater than 4 grams - neurological, cardiovascular and ECG
disturbances; serum chloro-quine level greater than 5 mg/L at the 4th hour.
o Dose
ingested 2 to 4 grams - neurological symptoms and ECG abnormalities, serum
chloroquine level of 2.5 to 5 mg/L.
o Dose
ingested less than 2 grams - no clinical symptoms, serum chloroquine level less
than 2.5 mg/L.
o The
occurrence of side effects in patients under chlo- roquine therapy is related
to chloroquine serum levels. No side effects occurred in patients with serum
levels less than 0.4 mg/L, whereas 80% of the patients with a level higher than
0.8 mg/L had side effects.
·
Serum level estimation by high pressure liquid
chroma-tography. Chloroquine levels higher than 5 mcg/ml are associated with
serious toxicity.
·
Like quinine, chloroquine fluoresces under UV light (254 nm
and 366 nm), and this property can be used to identify the substance in urine.
For this purpose, first add 0.1 ml of dilute HCl to 1 ml of urine and then
vortex-mix for 10 seconds. If there is fluorescence, add 1 gram of sodium
chloride, vortex-mix for 10 seconds and examine under UV light again. The urine
will not fluoresce any more.
·
Patients with suspected chloroquine overdose should receive
gastric decontamination, have an ECG performed and continuous cardiac
monitoring for a minimum of 6 hours after ingestion. Patients who are
asymptomatic during this period may be discharged after psychiatric evaluation
(if indicated). Monitor serum electrolytes and arterial blood gases in
symptomatic patients.
·
Stabilisation: The patient should be treated in
an intensivecare unit and continuous cardiac monitoring must be done.
Preparations should be made for airway protection (endotra-cheal intubation)
and mechanical ventilation. Defibrillator and cardiac pacemaker may be
required.
·
Correct anoxia by administering 100% oxygen.
·
Give diazepam (upto 10 mg IV slowly in adults; 0.1 to 0.3
mg/kg IV slowly in children).
·
If convulsions do not respond to diazepam, administer
phenytoin (15 mg/kg IV at 0.25 to 0.5 mg/kg/min). In severe cases,
neuromuscular paralysis may be required to avoid hyperthermia, severe acidosis,
and rhabdo-myolysis; continuous EEG monitoring is mandatory if neuromuscular
paralysis is used.
·
Correct hypotension by IV fluids, Trendelenberg posi-tion,
and dopamine or noradrenaline.
·
Adrenaline (1: 10,000) at a dose of 0.25 mcg/kg/min, until
systolic pressure is at least 100 mmHg.
·
Diazepam 2 mg/kg over 30 minutes
(preferably through motor-driven syringe type pump). The role of diazepam in
chloroquine poisoning has long been under study. It is believed that diazepam
apparently competes for cardiac chloroquine fixation sites.
·
Indications for noradrenaline therapy include massive
ingestion (> 5 gm chloroquine), very low systolic pres-sure (< 80 mmHg), and prolonged QRS
interval (> 120 milliseconds). Diazepam is indicated in patients with
convulsions, arrhythmias, QRS widening, hypotension, or circulatory collapse.
Decontamination: Gastric lavage may be done if the patientis seen within 2
hours of ingestion. Activated charcoal (1 gm/kg) is highly recommended.
Elimination: Acid diuresis though advocated by some inves-tigators is
best avoided. Exchange transfusion may be useful. Peritoneal dialysis and
haemodialysis are of little value in removing chloroquine from the body.
Chloroquine is well adsorbed by charcoal. However it has a large volume of
distribution and is rapidly distributed intracellularly; there-fore the amount
removed by haemoperfusion is not large.
·
Correct hypokalaemia with potassium (0.25 mEq/kg/ hr, upto a
maximum of 10 mEq/hr in 2 hours). Initial hypokalaemia should be corrected
cautiously because potassium and quinidine-like drugs have a synergistic
cardiotoxic effect, and intensive administration of potassium may lead to a
sudden hyperkalaemia.
·
Arrhythmias may require lignocaine. Ventricular
tachy-cardia/fibrillation can be corrected by direct current cardioversion.
Recurrence can be prevented by rapid pacemaker stimulation. Avoid class Ia
antiarrhythmics (quinidine, disopyramide, procainamide, aprindine), and most
class III antiarrhythmics (N- acetylprocaina-mide, sotalol).
·
Monitor liver and renal function.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2024 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.